Tukysa Approval Might Change The Case For Investing In Pfizer Stock (PFE)

Pfizer recently secured expanded FDA approval for TUKYSA as a chemotherapy free maintenance option in HER2 positive metastatic breast cancer and reported a wide slate of infectious disease vaccine data, including late stage Lyme, pneumococcal and RSV studies. The breadth of vaccine and oncology updates points to Pfizer leaning heavily on late stage pipelines and real world evidence to support future portfolio mix as older products face patent expiry and COVID sales pressure. We will now look...